WO2001027611A2 - Multiplex cytokine analysis - Google Patents
Multiplex cytokine analysis Download PDFInfo
- Publication number
- WO2001027611A2 WO2001027611A2 PCT/US2000/028635 US0028635W WO0127611A2 WO 2001027611 A2 WO2001027611 A2 WO 2001027611A2 US 0028635 W US0028635 W US 0028635W WO 0127611 A2 WO0127611 A2 WO 0127611A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cytokines
- sample
- array according
- different
- simultaneous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
Definitions
- the field of the invention is cytokine analysis.
- Cytokines are signaling proteins which are important in many diverse fields of research and in the diagnosis and clinical treatment of disease. For example, cytokines regulate the body's inflammatory response to infection. Tumor necrosis factor alpha, interleukin-1, interleukin-6, interleukin-8, and interleukin-12 are pro-inflammatory cytokines which have been implicated with sepsis. Anti-inflammatory cytokines such as interleukin-4 and interleukin-10 are also produced in response to infection to turn down the inflammatory response. Monitoring the serum levels of these and other cytokines can provide a measure of immune activity in the host. For example, several clinical studies have demonstrated a statistical link between TNF-a levels and severity of infection.
- ELISA directly measures the concentration of cytokine protein in serum or cell supematants.
- ELISA assays require no pre-assay preparation. The capital intensive step (detection) is not the longest step in ELISA which allows greater potential throughput than quantitative RT-PCR. These assays do, however, only measure the concentration of one cytokine per reaction which limits their throughput.
- the present invention relates to antibody array technology - a powerful tool for the parallel analysis of multiple gene products at the protein level. This technology complements that of DNA microarrays by facilitating the analysis of post transcriptional regulatory events. More particularly, the invention provides ELISA-type assays which analyze the concentrations of multiple proteins such as cytokines per reaction.
- the invention provides methods and compositions for the simultaneous, quantitative detection of cytokines in a sample.
- the methods use a solid phase array comprising a plurality of different antibodies arrayed in corresponding discrete array elements and specific for a corresponding plurality of different cytokines.
- the cytokines are selected from GM-CSF, ILl ⁇ . IL l ⁇ . IL2, IL4, IL6. IL7, IL8, IL10, IL12, TNF ⁇ , APO-1, sICAM-1, IFN- ⁇ , IFN- ⁇ , IL3, IL5.
- IL 13 is selected from GM-CSF, ILl ⁇ . IL l ⁇ . IL2, IL4, IL6. IL7, IL8, IL10, IL12, TNF ⁇ , APO-1, sICAM-1, IFN- ⁇ , IFN- ⁇ , IL3, IL5.
- the plurality is at least five, preferably at least eight, more preferably eleven; the antibodies are monoclonal; each antibody is bound to a different one of the corresponding cytokines; and the array is a microarray on a plastic or glass substrate made by contact deposition.
- the invention also provides methods of manufacturing and using the arrays for the simultaneous, quantitative detection of cytokines in samples.
- the terms "a” and “an” mean one or more and the term “or” means and/or.
- the methods use solid phase arrays of cytokine-specific antibodies arrayed in corresponding discrete array elements.
- the array elements are discrete regions of a substrate surface in fluid connection such that all the elements of the array can be incubated, washed, etc. in a single continuous medium.
- an array is distinct from assay formats where each specific antibody is separated in discrete, fluid-separated incubation wells as in a microtiter plate.
- the antibodv arravs mav be constructed bv a number of methods known in the art on a wide variety of substrates such as glass, silicon, plastics, nylon membranes, etc., including contact deposition, e.g. US Pat Nos. 5,807,522; 5,770,151, etc.; flow path-based methods, e.g. US Pat No. 5,384,261 ; dip-pen nanolithography-based methods, e.g. Piner, et al., Science Jan 29 1999: 661-663, etc.; etc. See also copending Serial No. 09/150,502, describing capillary printing systems which may be used for antibody array manufacturing.
- the antibodies are arrayed at corresponding discrete elements in high density, i.e. microarrays, generally at least 100, preferably at least 1000, more preferably at least 10,000, most preferably at least 100,000 discrete elements per square centimeter.
- each cytokine-specific antibody of the array is a monoclonal antibody.
- the antibodies may be specific for pluralities of a wide variety of cytokines, particularly lymphokines.
- Suitable cytokines may be purchased in purified or recombinant from commercial sources, expressed from commercially and/or publically available clones, and/or purified from tissues.
- the cytokines are of native human sequence, though homologs from a wide variety of animal species, particularly mammalian (e.g. murine) species are frequently available and may be used.
- mammalian (e.g. murine) species are frequently available and may be used.
- One unexpected finding of the invention was that a plurality of different cytokines could be simultaneously measured in the same, single incubation, particularly where the plurality is at least five, more particularly at least eight, most particularly at least eleven different cytokines.
- Exemplary human sequence cytokines shown to be so detectable are shown in Table 1.
- the disclosed arrays may be used to simultaneously, quantitatively detect such cytokines in samples.
- a wide variety of cytokine containing samples maybe subject to analysis by these methods, e.g. serum, urine, cerebral spinal fluid, etc.
- antibody array technology can measure gene expression in samples which contain no RNA. This greater availability results in the ability to conduct detailed statistical studies with antibodies arrays which are not possible with other assays.
- Incubation and wash conditions are readily determined empirically, as shown below, such that the targeted plurality of cytokines may be simultaneously assayed in a single incubation medium.
- a wide variety of methods may be used to detect the specifically bound cytokine analytes, including directly labeled cytokine specific antibody reagents, sandwich format immunoassays, cytokine-receptor binding assays, etc.
- Table 2 shows various cytokine pluralities simultaneously assayed by exemplary methods.
- EXEMPLARY EXPERIMENTAL PROTOCOLS Using the following protocols, we constructed a prototype antibody array for the simultaneous detection of 11 different cytokines in serum and cell supernatants. This assay was based on an ELISA sandwich format with chemiluminescent detection. Chemiluminescent detection, as opposed to fluorescent detection, requires no excitation of sample and allows the simultaneous detection of several different arrays at once resulting in a substantial increase in the throughput. Eleven distinct cytokines were successfully simultaneously, quantitatively assayed and the measurements validated by comparison with RT-PCR assays. Array construction. Capture antibodies (Biosource International) for 11 cytokines
- GM-CSF, ILl ⁇ , ILl ⁇ , IL2, IL4, IL6, IL7, IL8, ILIO, IL 12 and TNF ⁇ were spotted at a concentration of 0.5 mg/ml directly into the bottom of 12 well plates (Corning) which had been pre-coated for optimal antibody binding.
- Biotinylated bovine albumin was spotted at a concentration of 100 ug/ml as fiduciary material. Array elements were roughly 1000 microns in diameter with 3000 micron center to center spacing. Once spotted, plates were immediately covered and incubated overnight at 4°C.
- Arrays were then washed 4x with a solution of PBS (10 mM phosphate, 2.7 mM potassium chloride, 137 mM sodium chloride, pH 7.4) and 0.1% Tween-20 (Sigma) to remove unbound antibody. Plates were then blocked for 2 hours at room temperature with a solution containing 150 mM sodium, 4 mM potassium, 140 mM chloride, 10 mM phosphate (pH 7.4) and 5% BSA.
- PBS 10 mM phosphate, 2.7 mM potassium chloride, 137 mM sodium chloride, pH 7.4
- Tween-20 Sigma
- IL8, IL10, IL 12 and TNF ⁇ at a concentration of 0.5 ug/ml in 150 mM sodium, 4 mM potassium, 140 mM chloride, 10 mM phosphate (pH 7.4) and 10% BSA was added to each well and incubated with shaking at room temperature for 1 hour.
- the antibody solution was removed and 1 ml of a horseradish-peroxidase-streptavidin conjugate (HRP-STR), 0.2 ug/ml in HPE-dilution buffer (Research Diagnostics Inc.) was added to each array and incubated for
- Human THP-1 cells The human acute monocytic leukemia cell line THP-1 used in this study was maintained at 37°C in a humidified incubator containing 5% CO 2 . These cells were grown in RPMI-1640 medium (Gibco BRL) supplemented with 10% fetal calf serum (Gibco BRL), glucose (4.5 g/1), 5 x 10 "5 M b-mercaptoethanol, 1 mM sodium pyruvate, streptomycin (lOOmg/ml), and penicillin (100 U/ml). The cells were split into 6-well cell culture plates, 5 ml per plate, at a density of 5 x 10 5 cells/ml in complete RPMI1640 medium. Before activation of the cells with E.
- the cells were treated with 1.6 x 10 "9 M phorbol-12-myristate-13 acetate (PMA) (Sigma) for 48hr. After this incubation time the cells were treated with different concentrations (1 x lO'-lO 5 cells/ml) of exponentially grown E. coli and P. aeruginosa bacterial cells for 8hr. Both supernatant fluids and the cell pellet were collected and stored at -80 °C for later cytokine assays and RNA isolation / RT-PCR dectection of cytokine mRNA.
- PMA phorbol-12-myristate-13 acetate
- RNA isolation method with TRIzol Reagent (Gibco BRL) used is essentially as developed by Chomoczynski, P., and N. Sacchi.(1987, Anal. Biochem.
- the frozen cell pellets (about 2.5 x 10 6 cells) were lysed by resuspending in 1 ml of TRIzol Reagent (Gibco BRL) and repetitive pipetting. 200 ml of chloroform was than added and the samples were mixed vigorously by vortexing forl5 seconds. After centrifugation of the samples at 14,000 rpm for 15 min at 4°C, the colorless upper aqueous phase containing the RNA was transferred into a fresh RNase-free tube. The RNA was precipitated from the aqueous phase by mixing with 0.5 ml of isopropyl alcohol. Samples were incubated at room temperature for 10 min before centrifugation at 4°C for 7,500 rpm for 10 min.
- RNA pellet was washed once with 0.5 ml of 75% ethanol, before allowed to air dry for 10 min.
- concentration and purity of the RNA isolated was determined by measuring the OD 260 in 2 mM Na 2 PO 4 (pH8.0) in a spectrophotometer and by agarose gel electrophoresis.
- RT-PCR detection of cytokine mRNA The RT-PCR assay used in this work is essentially as described elsewhere (Murphy et al, 1993, J. Immunol. Methods. 162:21 1-223).
- Oligonucleotide primers targeting a 206-bp region of the human IL-6 gene Zilberstein et al, 1986, EMBO J.
- IL-6 specific PCR primers were designed based on the NCBI sequence query for the human IL-6 gene (accession number X04430). Oligonucleotide primers targeting a 107-bp region of the human IL-l ⁇ gene (Nishida et al, 1987) were used to detect IL-l ⁇ specific mRNA in untreated and treated THP-1 cells. These IL-l ⁇ specific PCR primers were designed based on the NCBI sequence query for the human IL-l ⁇ gene (accession number Ml 5330). All the primers were prepared by Operon (Alameda, CA).
- RT (reverse transcriptase) reactions were carried out in a final volume of 20 ml containing 1 mg of total RNA and the components supplied by PE Applied Biosystems (Foster City, CA) in the TaqMan Gold RT-PCR kit. RT reactions were performed as described in the kit protocol. For the following PCR reaction 1 ml of the RT reaction sample was used in a final volume of 30 ml containing all the components supplied by PE Applied Biosystems in the TaqMan Gold
- RT-PCR kit PCR reactions were performed as described in the kit protocol. 10 ml of each PCR product was loaded onto a 3% NuSieve/l%SeaKem GTG Agarose gel (FMC Bio- Products, Rockland, ME) in lxTBE buffer and subsequent electrophoresis was performed at 200V for 30 - 45 min. All publications and patent applications cited in this specification and all references cited therein are herein incorporated by reference as if each individual publication or patent application or reference were specifically and individually indicated to be incorporated by reference.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measurement Of Radiation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides methods and compositions for the simultaneous, quantitative detection of cytokines in a sample. The methods use a solid phase array comprising a plurality of different antibodies arrayed in corresponding discrete array elements and specific for a corresponding plurality of different cytokines. The invention also provides methods of manufacturing and using the arrays for the simultaneous, quantitative detection of cytokines in samples.
Description
Multiplex Cytokine Analysis
INTRODUCTION Field of the Invention The field of the invention is cytokine analysis.
Background
Cytokines are signaling proteins which are important in many diverse fields of research and in the diagnosis and clinical treatment of disease. For example, cytokines regulate the body's inflammatory response to infection. Tumor necrosis factor alpha, interleukin-1, interleukin-6, interleukin-8, and interleukin-12 are pro-inflammatory cytokines which have been implicated with sepsis. Anti-inflammatory cytokines such as interleukin-4 and interleukin-10 are also produced in response to infection to turn down the inflammatory response. Monitoring the serum levels of these and other cytokines can provide a measure of immune activity in the host. For example, several clinical studies have demonstrated a statistical link between TNF-a levels and severity of infection. Furthermore, research has indicated that different pathogens elicit unique patterns of cytokine expression. These data demonstrate that cytokines are excellent molecular markers for the diagnosis of septic inflammatory response. The current methods of choice for the analysis of cytokine expression in blood samples are quantitative RT-PCR and ELISA. Quantitative RT-PCR measures the level of cytokine mRNA in cells interest. This method requires the extraction of rnRNA from cells and thus requires a great deal of pre-assay preparation. The rate determining step of this assay is also the capital intensive step (requiring the expensive RT-PCR instrument) which severely limits scaling up the throughput of this method. Currently, only two cytokines can be detected per assay reaction with quantitative RT-PCR which also limits the potential throughput of this assay. ELISA, on the other hand, directly measures the concentration of cytokine protein in serum or cell supematants. ELISA assays require no pre-assay preparation. The capital intensive step (detection) is not the longest step in ELISA which allows greater potential throughput than quantitative RT-PCR. These assays do, however, only measure the concentration of one cytokine per reaction which limits their throughput.
The present invention relates to antibody array technology - a powerful tool for the parallel analysis of multiple gene products at the protein level. This technology complements that of DNA microarrays by facilitating the analysis of post transcriptional regulatory events. More particularly, the invention provides ELISA-type assays which analyze the concentrations of multiple proteins such as cytokines per reaction.
SUMMARY OF THE INVENTION The invention provides methods and compositions for the simultaneous, quantitative detection of cytokines in a sample. The methods use a solid phase array comprising a plurality of different antibodies arrayed in corresponding discrete array elements and specific for a corresponding plurality of different cytokines. In particular embodiments, the cytokines are selected from GM-CSF, ILlα. IL l β. IL2, IL4, IL6. IL7, IL8, IL10, IL12, TNFα, APO-1, sICAM-1, IFN-α, IFN-γ, IL3, IL5. IL 13. IL15, IL16, MCP-1, SAA and sVCAM-1; the plurality is at least five, preferably at least eight, more preferably eleven; the antibodies are monoclonal; each antibody is bound to a different one of the corresponding cytokines; and the array is a microarray on a plastic or glass substrate made by contact deposition. The invention also provides methods of manufacturing and using the arrays for the simultaneous, quantitative detection of cytokines in samples.
DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION
The following descriptions of particular embodiments and examples are offered by way of illustration and not by way of limitation. Unless contraindicated or noted otherwise, in these descriptions and throughout this specification, the terms "a" and "an" mean one or more and the term "or" means and/or. The methods use solid phase arrays of cytokine-specific antibodies arrayed in corresponding discrete array elements. The array elements are discrete regions of a substrate surface in fluid connection such that all the elements of the array can be incubated, washed, etc. in a single continuous medium. Hence, an array is distinct from assay formats where each specific antibody is separated in discrete, fluid-separated incubation wells as in a microtiter plate.
The antibodv arravs mav be constructed bv a number of methods known in the art on a
wide variety of substrates such as glass, silicon, plastics, nylon membranes, etc., including contact deposition, e.g. US Pat Nos. 5,807,522; 5,770,151, etc.; flow path-based methods, e.g. US Pat No. 5,384,261 ; dip-pen nanolithography-based methods, e.g. Piner, et al., Science Jan 29 1999: 661-663, etc.; etc. See also copending Serial No. 09/150,502, describing capillary printing systems which may be used for antibody array manufacturing. In a preferred embodiment, the antibodies are arrayed at corresponding discrete elements in high density, i.e. microarrays, generally at least 100, preferably at least 1000, more preferably at least 10,000, most preferably at least 100,000 discrete elements per square centimeter.
The antibodies may be intact or fragments, purified or recombinantly expressed, monoclonal or polyclonal and may be affinity purified. In a particular embodiment, each cytokine-specific antibody of the array is a monoclonal antibody.
The antibodies may be specific for pluralities of a wide variety of cytokines, particularly lymphokines. Suitable cytokines may be purchased in purified or recombinant from commercial sources, expressed from commercially and/or publically available clones, and/or purified from tissues. In a particular embodiment, the cytokines are of native human sequence, though homologs from a wide variety of animal species, particularly mammalian (e.g. murine) species are frequently available and may be used. One unexpected finding of the invention was that a plurality of different cytokines could be simultaneously measured in the same, single incubation, particularly where the plurality is at least five, more particularly at least eight, most particularly at least eleven different cytokines. Exemplary human sequence cytokines shown to be so detectable are shown in Table 1.
Table 1. Cytokines shown to be specifically, quantitatively detectable in muliplex lmmunoassavs.
1 Intercellular Adhesion Molecule
2 Macrophage Chemoattractant Protein
3 Serum Amyloid A
4 Soluble Vascular Cell Adhesion Molecule
Accordingly, the disclosed arrays may be used to simultaneously, quantitatively detect such cytokines in samples. A wide variety of cytokine containing samples maybe subject to analysis by these methods, e.g. serum, urine, cerebral spinal fluid, etc. Furthermore, unlike PCR-based methods, antibody array technology can measure gene expression in samples which contain no RNA. This greater availability results in the ability to conduct detailed statistical studies with antibodies arrays which are not possible with other assays.
Incubation and wash conditions are readily determined empirically, as shown below, such that the targeted plurality of cytokines may be simultaneously assayed in a single incubation medium. A wide variety of methods may be used to detect the specifically bound cytokine analytes, including directly labeled cytokine specific antibody reagents, sandwich format immunoassays, cytokine-receptor binding assays, etc. Table 2 shows various cytokine pluralities simultaneously assayed by exemplary methods.
(GM-CSF, ILlα, ILlβ, IL2, IL4, IL6, IL7, IL8, ILIO, IL 12 and TNFα) were spotted at a concentration of 0.5 mg/ml directly into the bottom of 12 well plates (Corning) which had been pre-coated for optimal antibody binding. Biotinylated bovine albumin was spotted at a concentration of 100 ug/ml as fiduciary material. Array elements were roughly 1000 microns in diameter with 3000 micron center to center spacing. Once spotted, plates were immediately covered and incubated overnight at 4°C. Arrays were then washed 4x with a solution of PBS (10 mM phosphate, 2.7 mM potassium chloride, 137 mM sodium chloride, pH 7.4) and 0.1% Tween-20 (Sigma) to remove unbound antibody. Plates were then blocked for 2 hours at room temperature with a solution containing 150 mM sodium, 4 mM potassium, 140 mM chloride, 10 mM phosphate (pH 7.4) and 5% BSA.
Assay conditions. The BSA solution was removed from each array followed by 4 washes with a solution of 0.005% tween-20 in PBS. 1 ml of sample was then applied to each array and incubated with shaking (120 rpm) for 2 hours at room temperature. Samples were removed and arrays washed 4x with 0.005% tween-20 in PBS. 1 ml of a solution containing biotinylated antibodies to each of the 11 cytokines (GM-CSF, ILlα, ILlβ, IL2, IL4, IL6, IL7,
IL8, IL10, IL 12 and TNFα) at a concentration of 0.5 ug/ml in 150 mM sodium, 4 mM potassium, 140 mM chloride, 10 mM phosphate (pH 7.4) and 10% BSA was added to each well and incubated with shaking at room temperature for 1 hour. The antibody solution was removed and 1 ml of a horseradish-peroxidase-streptavidin conjugate (HRP-STR), 0.2 ug/ml in HPE-dilution buffer (Research Diagnostics Inc.) was added to each array and incubated for
30 minutes at room temperature with shaking. The HRP-STR solution was removed and
arrays washed 4X with 0.005% Tween-20 in PBS solution. SuperSignal™ (Pierce) chemiluminescent substrate was mixed 1 :1 with provided peroxide solution, 500 ul of this mixture was added to each array, and the entire plate imaged simultaneously with a peltier cooled CCD camera imaging system (Chemilmager™ 4000, Alpha Innotech Co.). X-Ray film can also be used as a detection system. Data can be quantitated with any convenient image analysis program.
Human THP-1 cells. The human acute monocytic leukemia cell line THP-1 used in this study was maintained at 37°C in a humidified incubator containing 5% CO2. These cells were grown in RPMI-1640 medium (Gibco BRL) supplemented with 10% fetal calf serum (Gibco BRL), glucose (4.5 g/1), 5 x 10"5 M b-mercaptoethanol, 1 mM sodium pyruvate, streptomycin (lOOmg/ml), and penicillin (100 U/ml). The cells were split into 6-well cell culture plates, 5 ml per plate, at a density of 5 x 105 cells/ml in complete RPMI1640 medium. Before activation of the cells with E. coli or P. aeruginosa as inflammantory stimuli, the cells were treated with 1.6 x 10"9 M phorbol-12-myristate-13 acetate (PMA) (Sigma) for 48hr. After this incubation time the cells were treated with different concentrations (1 x lO'-lO5 cells/ml) of exponentially grown E. coli and P. aeruginosa bacterial cells for 8hr. Both supernatant fluids and the cell pellet were collected and stored at -80 °C for later cytokine assays and RNA isolation / RT-PCR dectection of cytokine mRNA.
Isolation of RNA. The RNA isolation method with TRIzol Reagent (Gibco BRL) used is essentially as developed by Chomoczynski, P., and N. Sacchi.(1987, Anal. Biochem.
162:156-159). The frozen cell pellets (about 2.5 x 106 cells) were lysed by resuspending in 1 ml of TRIzol Reagent (Gibco BRL) and repetitive pipetting. 200 ml of chloroform was than added and the samples were mixed vigorously by vortexing forl5 seconds. After centrifugation of the samples at 14,000 rpm for 15 min at 4°C, the colorless upper aqueous phase containing the RNA was transferred into a fresh RNase-free tube. The RNA was precipitated from the aqueous phase by mixing with 0.5 ml of isopropyl alcohol. Samples were incubated at room temperature for 10 min before centrifugation at 4°C for 7,500 rpm for 10 min. The RNA pellet was washed once with 0.5 ml of 75% ethanol, before allowed to air dry for 10 min. The concentration and purity of the RNA isolated was determined by measuring the OD260 in 2 mM Na2PO4 (pH8.0) in a spectrophotometer and by agarose gel electrophoresis.
RT-PCR detection of cytokine mRNA. The RT-PCR assay used in this work is essentially as described elsewhere (Murphy et al, 1993, J. Immunol. Methods. 162:21 1-223). Oligonucleotide primers targeting a 206-bp region of the human IL-6 gene (Zilberstein et al, 1986, EMBO J. 5:2529-37) were used to detect IL-6 specific mRNA in treated THP-1 cells. These IL-6 specific PCR primers were designed based on the NCBI sequence query for the human IL-6 gene (accession number X04430). Oligonucleotide primers targeting a 107-bp region of the human IL-lβ gene (Nishida et al, 1987) were used to detect IL-lβ specific mRNA in untreated and treated THP-1 cells. These IL-lβ specific PCR primers were designed based on the NCBI sequence query for the human IL-lβ gene (accession number Ml 5330). All the primers were prepared by Operon (Alameda, CA). RT (reverse transcriptase) reactions were carried out in a final volume of 20 ml containing 1 mg of total RNA and the components supplied by PE Applied Biosystems (Foster City, CA) in the TaqMan Gold RT-PCR kit. RT reactions were performed as described in the kit protocol. For the following PCR reaction 1 ml of the RT reaction sample was used in a final volume of 30 ml containing all the components supplied by PE Applied Biosystems in the TaqMan Gold
RT-PCR kit. PCR reactions were performed as described in the kit protocol. 10 ml of each PCR product was loaded onto a 3% NuSieve/l%SeaKem GTG Agarose gel (FMC Bio- Products, Rockland, ME) in lxTBE buffer and subsequent electrophoresis was performed at 200V for 30 - 45 min. All publications and patent applications cited in this specification and all references cited therein are herein incorporated by reference as if each individual publication or patent application or reference were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
Claims
1. An array comprising at least five different antibodies arrayed in corresponding discrete array elements and specific for corresponding five different cytokines.
2. An array according to claim 1, comprising at least ten different antibodies arrayed in corresponding discrete array elements and specific for corresponding ten different cytokines.
3. An array according to claim 1, wherein the cytokines are selected from Table 1.
4. An array according to claim 2, wherein the cytokines are selected from Table 1.
5. An array according to claim 2, wherein the cytokines are GM-CSF, ILlα, ILlβ, IL2, IL4, IL6, IL7, IL8, ILIO, IL 12 and TNFα.
6. An array according to claim 1, wherein each antibody is specific for and bound to a different one of the corresponding cytokines.
7. An array according to claim 2, wherein each antibody is specific for and bound to a different one of the corresponding cytokines.
8. An array according to claim 3, wherein each antibody is specific for and bound to a different one of the corresponding cytokines.
9. An array according to claim 1, wherein the antibodies are monoclonal.
10. An array according to claim 2, wherein the antibodies are monoclonal.
11. An array according to claim 3. wherein the antibodies are monoclonal.
12. A method for the simultaneous, quantitative detection of cytokines in a sample, the method comprising the step of contacting the sample with an array according to claim 1, whereby at least five different sample cytokines are simultaneously quantitatively measured.
13. A method for the simultaneous, quantitative detection of cytokines in a sample, the method comprising the step of contacting the sample with an array according to claim 2, whereby at least ten different sample cytokines are simultaneously quantitatively measured.
14. A method for the simultaneous, quantitative detection of cytokines in a sample, the method comprising the step of contacting the sample with an array according to claim 3, whereby at least five different sample cytokines corresponding to those of Table 1 are simultaneously quantitatively measured.
15. A method for the simultaneous, quantitative detection of cytokines in a sample, the method comprising the step of contacting the sample with an array according to claim 4, whereby at least ten different sample cytokines corresponding to those of Table 1 are simultaneously quantitatively measured.
16. A method for the simultaneous, quantitative detection of cytokines in a sample, the method comprising the step of contacting the sample with an array according to claim 5, whereby sample cytokines GM-CSF, ILlα, ILlβ, IL2, IL4, IL6, IL7, IL8, ILIO, IL12 and TNFα. are simultaneously quantitatively measured.
17. A method for the simultaneous, quantitative detection of cytokines in a sample, the method comprising the step of contacting the sample with an array according to claim 9, whereby at least five different sample cytokines are simultaneously quantitatively measured.
18. A method for the simultaneous, quantitative detection of cytokines in a sample, the method comprising the step of contacting the sample with an array according to claim 10, whereby at least ten different sample cytokines are simultaneously quantitatively measured.
19. A method for the simultaneous, quantitative detection of cytokines in a sample, the method comprising the step of contacting the sample with an array according to claim 1 1, whereby at least five different sample cytokines corresponding to those of Table 1 are simultaneously quantitatively measured.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00970956A EP1222468B1 (en) | 1999-10-13 | 2000-10-13 | Multiplex cytokine analysis |
| AT00970956T ATE263375T1 (en) | 1999-10-13 | 2000-10-13 | MULTIPLE ANALYSIS OF CYTOKINES |
| AU80264/00A AU760486B2 (en) | 1999-10-13 | 2000-10-13 | Multiplex cytokine analysis |
| CA002385614A CA2385614A1 (en) | 1999-10-13 | 2000-10-13 | Multiplex cytokine analysis |
| DE60009533T DE60009533T2 (en) | 1999-10-13 | 2000-10-13 | MULTIPLE ANALYSIS OF CYTOKINES |
| JP2001530571A JP2003511696A (en) | 1999-10-13 | 2000-10-13 | Multiple cytokine analysis |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41729299A | 1999-10-13 | 1999-10-13 | |
| US09/417,292 | 1999-10-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2001027611A2 true WO2001027611A2 (en) | 2001-04-19 |
| WO2001027611A3 WO2001027611A3 (en) | 2001-10-25 |
Family
ID=23653363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2000/028635 Ceased WO2001027611A2 (en) | 1999-10-13 | 2000-10-13 | Multiplex cytokine analysis |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20030211550A1 (en) |
| EP (1) | EP1222468B1 (en) |
| JP (1) | JP2003511696A (en) |
| AT (1) | ATE263375T1 (en) |
| AU (1) | AU760486B2 (en) |
| CA (1) | CA2385614A1 (en) |
| DE (1) | DE60009533T2 (en) |
| WO (1) | WO2001027611A2 (en) |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005530983A (en) * | 2001-10-02 | 2005-10-13 | ノースウエスタン ユニヴァーシティ | Protein and peptide nanoarrays |
| EP1563083A4 (en) * | 2001-12-26 | 2006-03-22 | Molecular Staging Inc | Use of cytokines secreted by dendritic cells |
| EP1736780A1 (en) | 2005-06-24 | 2006-12-27 | Eppendorf Array Technologies S.A. | Method and means for detecting and/or quantifying hierarchical molecular change of a cell in response to an external stimulus |
| EP1837658A1 (en) * | 2006-03-22 | 2007-09-26 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Cytokine-based pyrogen test |
| WO2007130549A1 (en) * | 2006-05-02 | 2007-11-15 | Govt.Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Monoclonal antibody microarray |
| WO2007146401A3 (en) * | 2006-06-14 | 2009-02-26 | Cell Matrix Inc | Denatured collagen peptides and uses thereof |
| WO2009012140A3 (en) * | 2007-07-13 | 2009-03-05 | Prometheus Lab Inc | Drug selection for lung cancer therapy using antibody-based arrays |
| US7763248B2 (en) | 2001-11-26 | 2010-07-27 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
| US7763247B2 (en) | 2001-11-26 | 2010-07-27 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
| WO2011144583A1 (en) * | 2010-05-19 | 2011-11-24 | F. Hoffmann-La Roche Ag | Combination therapy and method for assessing resistance to treatment |
| US8163499B2 (en) | 2008-02-25 | 2012-04-24 | Prometheus Laboratories Inc. | Drug selection for breast cancer therapy using antibody-based arrays |
| US8617808B2 (en) | 2004-04-30 | 2013-12-31 | Mabtech Ab | Cultispot assay |
| US8658388B2 (en) | 2006-09-21 | 2014-02-25 | Nestec S.A. | Antibody-based arrays for detecting multiple signal transducers in rate circulating cells |
| WO2014041087A1 (en) | 2012-09-12 | 2014-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Muscle secretome and uses thereof |
| US8790872B2 (en) | 2004-04-30 | 2014-07-29 | Mabtech Ab | Non-elispot assay |
| US9664683B2 (en) | 2011-09-02 | 2017-05-30 | Pierian Holdings, Inc. | Profiling of signal pathway proteins to determine therapeutic efficacy |
| US9719995B2 (en) | 2011-02-03 | 2017-08-01 | Pierian Holdings, Inc. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
| US10473640B2 (en) | 2006-09-21 | 2019-11-12 | Société des Produits Nestlé S.A. | Drug selection for gastric cancer therapy using antibody-based arrays |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0227941D0 (en) * | 2002-11-29 | 2003-01-08 | Interbrew Sa | Beer line and flow restrictor |
| US20030153013A1 (en) * | 2002-11-07 | 2003-08-14 | Ruo-Pan Huang | Antibody-based protein array system |
| US20060084184A1 (en) * | 2004-10-19 | 2006-04-20 | Renovar Incorporated | Reagents for urine-based immunological assays |
| US20090068162A1 (en) * | 2004-11-17 | 2009-03-12 | Robert Sack | Stationary Phase Antibody Arrays for Trace Protein Analysis |
| US20150005186A1 (en) * | 2013-06-27 | 2015-01-01 | Jing-Feng Huang | Methods and devices for classifying and managing autoimmune and inflammatory conditions |
| WO2015023661A2 (en) * | 2013-08-12 | 2015-02-19 | Health Research, Inc. | Biomarkers for prostate cancer |
| EP3482202A4 (en) | 2016-07-11 | 2020-03-18 | Arizona Board of Regents on behalf of Arizona State University | SWEAT AS A BIOFLUID FOR ANALYSIS AND DISEASE DETECTION |
| CN106885898B (en) * | 2017-03-07 | 2019-02-22 | 杭州英邈生物科技有限公司 | A kind of composition for detecting plasma inflammatory cytokines natural antibody, kit, blocking agent and its clinical application |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4591570A (en) * | 1983-02-02 | 1986-05-27 | Centocor, Inc. | Matrix of antibody-coated spots for determination of antigens |
| US5804370A (en) * | 1994-06-08 | 1998-09-08 | Critichem Medical Products Limited | Early diagnosis of sepsis utilizing antigen-antibody interactions amplified by whole blood chemiluminescence |
| PT789588E (en) * | 1994-11-17 | 2005-05-31 | Univ South Florida | Process for the production of a medicament for the treatment of secondary immunodeficiency |
| CA2318175A1 (en) * | 1998-02-04 | 1999-08-12 | Invitrogen Corporation | Microarrays and uses therefor |
| US6197599B1 (en) * | 1998-07-30 | 2001-03-06 | Guorong Chin | Method to detect proteins |
-
2000
- 2000-10-13 AT AT00970956T patent/ATE263375T1/en not_active IP Right Cessation
- 2000-10-13 JP JP2001530571A patent/JP2003511696A/en active Pending
- 2000-10-13 CA CA002385614A patent/CA2385614A1/en not_active Abandoned
- 2000-10-13 AU AU80264/00A patent/AU760486B2/en not_active Ceased
- 2000-10-13 WO PCT/US2000/028635 patent/WO2001027611A2/en not_active Ceased
- 2000-10-13 EP EP00970956A patent/EP1222468B1/en not_active Revoked
- 2000-10-13 DE DE60009533T patent/DE60009533T2/en not_active Expired - Fee Related
-
2003
- 2003-05-23 US US10/444,563 patent/US20030211550A1/en not_active Abandoned
Cited By (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005530983A (en) * | 2001-10-02 | 2005-10-13 | ノースウエスタン ユニヴァーシティ | Protein and peptide nanoarrays |
| US7763247B2 (en) | 2001-11-26 | 2010-07-27 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
| US7763248B2 (en) | 2001-11-26 | 2010-07-27 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
| EP1563083A4 (en) * | 2001-12-26 | 2006-03-22 | Molecular Staging Inc | Use of cytokines secreted by dendritic cells |
| US8617808B2 (en) | 2004-04-30 | 2013-12-31 | Mabtech Ab | Cultispot assay |
| US8790872B2 (en) | 2004-04-30 | 2014-07-29 | Mabtech Ab | Non-elispot assay |
| EP1736780A1 (en) | 2005-06-24 | 2006-12-27 | Eppendorf Array Technologies S.A. | Method and means for detecting and/or quantifying hierarchical molecular change of a cell in response to an external stimulus |
| WO2007107370A1 (en) * | 2006-03-22 | 2007-09-27 | Paul-Ehrlich-Institut Bundesamt Für Sera Und Impfstoffe | Cytokine-based pyrogen test |
| EP1837658A1 (en) * | 2006-03-22 | 2007-09-26 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Cytokine-based pyrogen test |
| WO2007130549A1 (en) * | 2006-05-02 | 2007-11-15 | Govt.Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Monoclonal antibody microarray |
| WO2007146401A3 (en) * | 2006-06-14 | 2009-02-26 | Cell Matrix Inc | Denatured collagen peptides and uses thereof |
| US10527622B2 (en) | 2006-09-21 | 2020-01-07 | Société des Produits Nestlé S.A. | Antibody-based arrays for detecting multiple signal transducers in rare circulating cells |
| US10473640B2 (en) | 2006-09-21 | 2019-11-12 | Société des Produits Nestlé S.A. | Drug selection for gastric cancer therapy using antibody-based arrays |
| US9575066B2 (en) | 2006-09-21 | 2017-02-21 | Nestec S.A. | Antibody-based arrays for detecting multiple signal transducers in rare circulating cells |
| US9285369B2 (en) | 2006-09-21 | 2016-03-15 | Nestec S.A. | Antibody-based arrays for detecting multiple signal transducers in rare circulating cells |
| US8658388B2 (en) | 2006-09-21 | 2014-02-25 | Nestec S.A. | Antibody-based arrays for detecting multiple signal transducers in rate circulating cells |
| US9250243B2 (en) | 2006-09-21 | 2016-02-02 | Nestec S.A. | Drug selection for lung cancer therapy using antibody-based arrays |
| WO2009012140A3 (en) * | 2007-07-13 | 2009-03-05 | Prometheus Lab Inc | Drug selection for lung cancer therapy using antibody-based arrays |
| US9274116B2 (en) | 2008-02-25 | 2016-03-01 | Nestec S.A. | Drug selection for breast cancer therapy using antibody-based arrays |
| US8609349B2 (en) | 2008-02-25 | 2013-12-17 | Nestec S.A. | Drug selection for breast cancer therapy using antibody-based arrays |
| US10436786B2 (en) | 2008-02-25 | 2019-10-08 | Société des Produits Nestlé S.A. | Methods for detecting truncated receptors using antibody-based arrays |
| US8163499B2 (en) | 2008-02-25 | 2012-04-24 | Prometheus Laboratories Inc. | Drug selection for breast cancer therapy using antibody-based arrays |
| KR20150065931A (en) * | 2010-05-19 | 2015-06-15 | 에프. 호프만-라 로슈 아게 | Combination therapy and method for assessing resistance to treatment |
| KR101539138B1 (en) * | 2010-05-19 | 2015-07-23 | 에프. 호프만-라 로슈 아게 | Combination therapy and method for assessing resistance to treatment |
| US8309299B2 (en) | 2010-05-19 | 2012-11-13 | Hoffmann-La Roche Inc. | Combination therapy and method for assessing resistance to treatment |
| WO2011144583A1 (en) * | 2010-05-19 | 2011-11-24 | F. Hoffmann-La Roche Ag | Combination therapy and method for assessing resistance to treatment |
| US9719995B2 (en) | 2011-02-03 | 2017-08-01 | Pierian Holdings, Inc. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
| US10401364B2 (en) | 2011-02-03 | 2019-09-03 | Soiété Des Produits Nestlé S.A. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
| US9664683B2 (en) | 2011-09-02 | 2017-05-30 | Pierian Holdings, Inc. | Profiling of signal pathway proteins to determine therapeutic efficacy |
| WO2014041087A1 (en) | 2012-09-12 | 2014-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Muscle secretome and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| AU760486B2 (en) | 2003-05-15 |
| WO2001027611A3 (en) | 2001-10-25 |
| EP1222468A2 (en) | 2002-07-17 |
| AU8026400A (en) | 2001-04-23 |
| CA2385614A1 (en) | 2001-04-19 |
| US20030211550A1 (en) | 2003-11-13 |
| EP1222468B1 (en) | 2004-03-31 |
| JP2003511696A (en) | 2003-03-25 |
| DE60009533T2 (en) | 2005-01-27 |
| DE60009533D1 (en) | 2004-05-06 |
| ATE263375T1 (en) | 2004-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU760486B2 (en) | Multiplex cytokine analysis | |
| JP4711963B2 (en) | Methods using cytokine assays to diagnose, treat and evaluate inflammatory and autoimmune diseases | |
| EP1566635B1 (en) | Microwell array chip for detecting antigen-specific lymphocyte, method of detecting antigen-specific lymphocyte and method of cloning antigen-specific lymphocyte antigen receptor gene | |
| EP2370814B1 (en) | Method for diagnosing allergic reactions | |
| Sachdeva et al. | Cytokine quantitation: technologies and applications | |
| Robak et al. | Serum levels of interleukin‐6 type cytokines and soluble interleukin‐6 receptor in patients with rheumatoid arthritis | |
| Navikas et al. | Augmented expression of tumour necrosis factor-α and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis | |
| Yu et al. | Immunopathological roles of cytokines, chemokines, signaling molecules, and pattern‐recognition receptors in systemic lupus erythematosus | |
| KR20160002756A (en) | Improved methods for conducting multiplexed assays | |
| JP7248788B2 (en) | Biomarkers of Systemic Lupus Erythematosus (SLE) Disease Active Immune Index to Characterize Disease Activity | |
| Chetaille Nézondet et al. | The evaluation of cytokines to help establish diagnosis and guide treatment of autoinflammatory and autoimmune diseases | |
| CA3049778C (en) | Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare | |
| WO2007001817A1 (en) | Cell-based microarrays, and methods for their preparation and use | |
| Kiaii et al. | T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile | |
| ES2198496T5 (en) | A PROCEDURE FOR IN VITRO ANALYSIS OF TOXIC AND ALLERGEN SUBSTANCES. | |
| US9513286B2 (en) | Differentially expressed genes in large granular lymphocyte leukemia | |
| Gilbertson-White et al. | Methodologic issues in the measurement of cytokines to elucidate the biological basis for cancer symptoms | |
| US10280466B2 (en) | Method and kit for dynamic gene expression monitoring | |
| AU8026400B2 (en) | ||
| WO2006100673A2 (en) | Methods of individually optimizing treatment for an inflammation associated disease | |
| JP2020531439A (en) | Compositions and Methods for Treatment and Treatment Choices for Atopic Dermatitis | |
| WO2003056896A2 (en) | Use of cytokines secreted by dendritic cells | |
| Wu et al. | Synovial Fluid Autoantibodies and Cytokines in Rheumatoid Arthritis Potential Biomarkers and Insight into Disease Pathogenesis | |
| EP0276984A2 (en) | Measuring anti-DNA antibodies | |
| Yamadab et al. | Expression of mRNA for RANTES in human eosinophils |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 80264/00 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2385614 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 530571 Kind code of ref document: A Format of ref document f/p: F |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2000970956 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2000970956 Country of ref document: EP |
|
| WWG | Wipo information: grant in national office |
Ref document number: 80264/00 Country of ref document: AU |
|
| WWG | Wipo information: grant in national office |
Ref document number: 2000970956 Country of ref document: EP |